MediciNova Completes Phase 2 MN-001 Trial in NAFLD
LA JOLLA, Calif., May 26, 2026 MediciNova announced the completion of the Last Patient Last Visit (LPLV) in its...
metabolic disease
Advertisement
Lilly’s Foundayo Shows Strong Weight Loss in Seniors
Indianapolis, Indiana, USA – May 22, 2026 Eli Lilly and Company announced new clinical analysis from the Phase 3...
MetaVia Highlights Vanoglipel’s MASH Fibrosis Potential
CAMBRIDGE, Mass., May 20, 2026 MetaVia Inc. has announced the publication of new peer-reviewed preclinical research supporting the anti-fibrotic...
Mirai Bio Expands LNP Delivery Into Adipocyte Tissue
CAMBRIDGE, Mass., May 14, 2026 Mirai Bio presented new preclinical data at the American Society of Gene and Cell...
Innovent Highlights Obesity Pipeline at ADA 2026
SAN FRANCISCO and SUZHOU, China, May 12, 2026 Innovent Biologics announced that it will present multiple clinical and preclinical...
Advertisements
Eli Lilly Strengthens GLP-1 Leadership With New Foundayo Trial Results
INDIANAPOLIS, May 12, 2026 Eli Lilly and Company has reported positive results from two major late-phase obesity trials showing...
Novo Nordisk Expands Wegovy Leadership at ECO 2026
BAGSVAERD, Denmark, May 12, 2026 Novo Nordisk announced new clinical findings at the 2026 European Congress on Obesity (ECO...
Novo Nordisk Reports 28% Weight Loss With Higher-Dose Wegovy
Bagsværd, Denmark, May 12, 2026 Novo Nordisk presented new analyses from its pivotal STEP UP clinical trial at the...
Boehringer Survodutide Shows 16.6% Weight Loss in Phase III
INGELHEIM, GERMANY, April 28, 2026 Boehringer Ingelheim has announced positive Phase III results for its investigational dual agonist survodutide,...
Anaxiom AVOS Device Shows Safe Early Obesity Results
LAGUNA HILLS, Calif., April 2026 Anaxiom Corporation has announced encouraging early clinical results from its first-in-human study of the...
Advertisement
